HICKY Secures Funding from Tokyo Wellness Impact Fund and CJS Fund No. 2 to Develop Innovative Treatment for Central Sleep Apnea in Heart Failure Patients
NQ Score
94/100
N1 Content Completeness
10
AI Summary (NQ-processed)
HICKY, a developer of innovative treatment devices for central sleep apnea, has raised funds to accelerate the development of its stent-type, wireless-powered neurostimulation device.
AI Analysis
Frequently Asked Questions
- Q: What are the features of HICKY's device?
- A: It is a minimally invasive neurostimulation device that combines a stent-type structure with wireless power transfer, eliminating the need for a subcutaneous generator.
- Q: What is Central Sleep Apnea (CSA)?
- A: A condition where breathing stops during sleep, which is a serious issue linked to worsening heart failure and increased mortality risk.
- Q: What is the purpose of this funding?
- A: To accelerate device miniaturization, advance preclinical and clinical trials, handle regulatory affairs, and build a global clinical collaboration network.